Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia.

[1]  Daniel B. Aruch,et al.  Contemporary approach to essential thrombocythemia and polycythemia vera , 2016, Current opinion in hematology.

[2]  T. Barbui,et al.  New and treatment‐relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera , 2015, American journal of hematology.

[3]  J. Smith-Gagen,et al.  Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011 , 2015, Journal of Cancer Research and Clinical Oncology.

[4]  P. de Paepe,et al.  Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations , 2015, Haematologica.

[5]  V. Bhatt Leukemic transformation in essential thrombocythemia. , 2014, Future oncology.

[6]  T. Barbui,et al.  Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. , 2014, Blood.

[7]  M. Björkholm,et al.  Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? , 2014, Best practice & research. Clinical haematology.

[8]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[9]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[10]  R. Kralovics,et al.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. , 2013, Blood.

[11]  P. Campbell,et al.  How I treat essential thrombocythemia. , 2011, Blood.

[12]  P. Johansson,et al.  The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera , 2011, European journal of haematology.

[13]  Juergen Thiele,et al.  The 2008 World Health Organization classification system for myeloproliferative neoplasms , 2009, Cancer.

[14]  A. Tefferi,et al.  Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance , 2009, European journal of haematology.

[15]  P. Campbell,et al.  Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Green,et al.  Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. , 2008, The New England journal of medicine.

[17]  C. Pascutto,et al.  Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients , 2008, Haematologica.

[18]  C. Bloomfield,et al.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.

[19]  A. Tefferi,et al.  Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients , 2007, Leukemia.

[20]  R. Mesa,et al.  JAK2V617F and leukemic transformation in myelofibrosis with myeloid metaplasia , 2006 .

[21]  D. Larson,et al.  Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. , 2006, Mayo Clinic proceedings.

[22]  J. D. van der Walt,et al.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. , 2005, The New England journal of medicine.

[23]  M. Cazzola,et al.  Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.

[24]  T. Barbui,et al.  Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long‐term follow‐up of a randomized clinical trial , 2000, British journal of haematology.

[25]  A. Green,et al.  7 Molecular genetics and cytogenetics of myeloproliferative disorders , 1998 .

[26]  T. C. Liu,et al.  Multiple factors in the transformation of essential thrombocythemia to acute leukemia or myelodysplastic syndrome. , 1998, Blood.

[27]  G. Tobelem 9 Essential thrombocythaemia , 1989 .

[28]  Peter J Campbell,et al.  Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. , 2008, Blood.

[29]  J. D. van der Walt,et al.  European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.

[30]  R. Fonseca,et al.  A long-term retrospective study of young women with essential thrombocythemia. , 2001, Mayo Clinic proceedings.

[31]  Arturo Pereira,et al.  Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. , 1991, Acta haematologica.